Skip to content
Screener

Amphastar Pharmaceuticals AMPH Operating Income

Operating Income at other companies

Halozyme Therapeutics logo
Halozyme TherapeuticsHALO
$287.65M+42.1%
Emergent Biosolutions logo
Emergent BiosolutionsEBS
-$125.1M-7,919%
Viatris logo
ViatrisVTRS
$6.3M-97.3%
Aquestive Therapeutics, Inc. logo
Aquestive Therapeutics, Inc.AQST
-$4.2M+78.3%
Opko Health logo
Opko HealthOPK
-$6.97M+88.4%
AptarGroup logo
AptarGroupATR
$107.5M-5.2%

Other financials

Income statement

See full
Revenue$183.9M+5.4%
Gross profit$93.5M+8.1%
Net income$30.3M-2.2%
EPS (diluted)$0.67+4.7%

Balance sheet

See full
Cash & equivalents$223.6M+19.1%
Total debt$688.5M+5.0%
Total equity$445.5M—
Total assets$1.7B+8.0%

Cash flow

See full
Operating cash flow$51.3M+44.2%
CapEx$8.6M-18.7%
Free cash flow$42.7M+70.7%

Valuation

See full
Market cap$873.48M-28.0%
Enterprise value$1.34B-20.6%
P/E11.1×+2.1×
P/S1.2×-0.5×

Profitability

See full
Gross margin47.7%-2.2pp
Operating margin15.7%-9.5pp
Net margin10.8%-7.9pp
FCF margin20.9%+5.4pp

Returns & leverage

See full
Return on equity14.7%—
Debt / equity0.2×—
Current ratio2.4×-0.9×

Where this comes from

Reported directly by Amphastar Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The source filing: Amphastar Pharmaceuticals’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:50 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001297184-26-000047
Line itemThree Months Ended / June 30, 2026Three Months Ended / June 30, 2025Six Months Ended / June 30, 2026Six Months Ended / June 30, 2025
General and administrative18,24213,99136,27029,987
Research and development22,16420,08048,90140,176
Total operating expenses53,74144,306110,43392,264
Income from operations39,72942,18453,35979,477
Non-operating expenses:
Interest income2,2871,9214,6874,010
Interest expense(6,659)(6,281)(13,212)(12,567)
Other income (expenses), net3,1871,5113,762(723)

Item 1. Financial Statements (unaudited)

FAQ

What is Amphastar Pharmaceuticals's operating income?
Amphastar Pharmaceuticals (AMPH) reported operating income of $39.73M in Q2 2026.
How has Amphastar Pharmaceuticals's operating income changed year-over-year?
Amphastar Pharmaceuticals's operating income decreased by 5.8% year-over-year, from $42.18M to $39.73M.
What is the long-term trend for Amphastar Pharmaceuticals's operating income?
Over 4 years (2021 to 2025), Amphastar Pharmaceuticals's operating income has grown at a 19.1% compound annual growth rate (CAGR), from $69.89M to $140.4M.
What does operating income mean?
Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.

Ask your AI about Amphastar Pharmaceuticals's operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude